Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2017

Open Access 01-12-2017 | Case report

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report

Authors: Linda Sakhri, Julian Pinsolle, Denis Moro-Sibilot, Hélène Pluchart

Published in: Journal of Medical Case Reports | Issue 1/2017

Login to get access

Abstract

Background

We describe a case of pemetrexed toxicities related to reabsorption by an ileal neobladder, which caused prolonged hematotoxicity and nephrotoxicity.

Case presentation

A 59-year-old white man was diagnosed with metastatic wild-type adenocarcinoma of the upper lobe of his right lung. After a first cycle of cisplatin and pemetrexed, he had unusually prolonged aplasia and acute kidney injury.
The prolonged aplasia was caused by pemetrexed reabsorption by the ileal mucosa of the neobladder as pemetrexed was eliminated renally in an active form and is partly lipophilic.

Conclusions

Pemetrexed may be reabsorbed by the ileal mucosa of the neobladder because of its hydrophobic structure and renal excretion in its active form. Acute urinary retention may maintain this phenomenon. Published data excluded a potential role for cisplatin in this toxicity; furthermore, we could not assess pemetrexed concentrations in the blood or urine as these assay techniques are not validated. Thus, care is needed when giving chemotherapy to patients with a neobladder.
Literature
1.
go back to reference Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3543–51.CrossRef Scagliotti GV, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3543–51.CrossRef
2.
go back to reference Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (alimta). Oncologist. 2004;9:482–8.CrossRefPubMed Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (alimta). Oncologist. 2004;9:482–8.CrossRefPubMed
3.
go back to reference Kuzur ME, Greco FA. Cisplatin-induced anemia. N Engl J Med. 1980;303:110–1.PubMed Kuzur ME, Greco FA. Cisplatin-induced anemia. N Engl J Med. 1980;303:110–1.PubMed
4.
go back to reference Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.CrossRefPubMed Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23.CrossRefPubMed
5.
go back to reference von der Maase H. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17:1533–8.CrossRefPubMed von der Maase H. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol. 2006;17:1533–8.CrossRefPubMed
6.
go back to reference Dreicer R, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the eastern cooperative oncology group. Cancer. 2008;112:2671–5.CrossRefPubMedPubMedCentral Dreicer R, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the eastern cooperative oncology group. Cancer. 2008;112:2671–5.CrossRefPubMedPubMedCentral
7.
go back to reference Sweeney CJ, Phase II. Study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451–7.CrossRefPubMed Sweeney CJ, Phase II. Study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451–7.CrossRefPubMed
8.
go back to reference Choi YJ, et al. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17). Br J Cancer. 2015;112:260–5.CrossRefPubMed Choi YJ, et al. Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17). Br J Cancer. 2015;112:260–5.CrossRefPubMed
9.
go back to reference Galsky MD, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265–70.CrossRefPubMed Galsky MD, et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265–70.CrossRefPubMed
10.
go back to reference Hutson TE, et al. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs. 2008;26:151–8.CrossRefPubMed Hutson TE, et al. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs. 2008;26:151–8.CrossRefPubMed
11.
go back to reference Hendricksen K. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs. Clin Cancer Res. 2006;12:2597–601.CrossRefPubMed Hendricksen K. Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs. Clin Cancer Res. 2006;12:2597–601.CrossRefPubMed
12.
go back to reference Rinaldi DA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44:372–80.CrossRefPubMed Rinaldi DA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44:372–80.CrossRefPubMed
Metadata
Title
Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
Authors
Linda Sakhri
Julian Pinsolle
Denis Moro-Sibilot
Hélène Pluchart
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2017
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-017-1436-7

Other articles of this Issue 1/2017

Journal of Medical Case Reports 1/2017 Go to the issue